Finally, Src has been identified as an attractive target in oncology but Src inhibitors developed for the clinic gave disappointing results in colon cancer, probably because of high toxicity and inefficient Src signaling inhibition [3]. The gene discussed is SRC; the disease is malignant colon neoplasm.